Literature DB >> 34749265

Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity.

Amanda N Pinski1, Ilhem Messaoudi2.   

Abstract

Zaire Ebola virus (EBOV) is a member of the Filoviridae family. Infection with EBOV causes Ebola virus disease (EVD) characterized by excessive inflammation, lymphocyte death, coagulopathy, and multi-organ failure. In 2019, the FDA-approved the first anti-EBOV vaccine, rVSV-EBOV-GP (Ervebo® by Merck). This live-recombinant vaccine confers both prophylactic and therapeutic protection to nonhuman primates and humans. While mechanisms conferring prophylactic protection are well-investigated, those underlying protection conferred shortly before and after exposure to EBOV remain poorly understood. In this review, we review data from in vitro and in vivo studies analyzing early immune responses to rVSV-EBOV-GP and discuss the role of innate immune activation in therapeutic protection.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34749265      PMCID： PMC8884032          DOI： 10.1016/j.coviro.2021.10.007

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN： 1879-6257            Impact factor:   7.090


  133 in total

1.  Randomized, Blinded, Dose-Ranging Trial of an Ebola Virus Glycoprotein Nanoparticle Vaccine With Matrix-M Adjuvant in Healthy Adults.

Authors:  Louis Fries; Iksung Cho; Verena Krähling; Sarah K Fehling; Thomas Strecker; Stephan Becker; Jay W Hooper; Steven A Kwilas; Sapeckshita Agrawal; Judy Wen; Maggie Lewis; Amy Fix; Nigel Thomas; David Flyer; Gale Smith; Gregory Glenn
Journal:  J Infect Dis       Date:  2020-07-23       Impact factor: 5.226

2.  Attenuated vesicular stomatitis viruses as vaccine vectors.

Authors:  A Roberts; L Buonocore; R Price; J Forman; J K Rose
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  NKp30-dependent cytolysis of filovirus-infected human dendritic cells.

Authors:  Claudette L Fuller; Gordon Ruthel; Kelly L Warfield; Dana L Swenson; Catharine M Bosio; M Javad Aman; Sina Bavari
Journal:  Cell Microbiol       Date:  2007-04       Impact factor: 3.715

4.  Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Joan B Geisbert; Douglas S Reed; Friederike Feldmann; Allen Grolla; Ute Ströher; Elizabeth A Fritz; Lisa E Hensley; Steven M Jones; Heinz Feldmann
Journal:  Vaccine       Date:  2008-10-18       Impact factor: 3.641

5.  Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1.

Authors:  Kathleen C Prins; Washington B Cárdenas; Christopher F Basler
Journal:  J Virol       Date:  2009-01-19       Impact factor: 5.103

6.  Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates.

Authors:  Chad E Mire; Joan B Geisbert; Krystle N Agans; Benjamin A Satterfield; Krista M Versteeg; Elizabeth A Fritz; Heinz Feldmann; Lisa E Hensley; Thomas W Geisbert
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

Review 7.  Ebola Virus Entry: From Molecular Characterization to Drug Discovery.

Authors:  Cristiano Salata; Arianna Calistri; Gualtiero Alvisi; Michele Celestino; Cristina Parolin; Giorgio Palù
Journal:  Viruses       Date:  2019-03-19       Impact factor: 5.048

8.  Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013-16 West Africa epidemic.

Authors:  T R W Tipton; Y Hall; J A Bore; A White; L S Sibley; C Sarfas; Y Yuki; M Martin; S Longet; J Mellors; K Ewer; S Günther; M Carrington; M K Kondé; M W Carroll
Journal:  Nat Commun       Date:  2021-02-19       Impact factor: 14.919

9.  Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses.

Authors:  Xiangguo Qiu; Lisa Fernando; Judie B Alimonti; P Leno Melito; Friedericke Feldmann; Daryl Dick; Ute Ströher; Heinz Feldmann; Steven M Jones
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.